Call for patient input on TBC (filgotinib) for rheumatoid arthritis (RA) |
Introduction
Do you have rheumatoid arthritis? If so, we need your valuable input.
The Common Drug review, as part of the CADTH review process, seeks to hear from patients about their disease experiences to help the reviewers better understand any unmet needs a new medication could help to address.
Background
All new drugs are submitted for review by the joint Federal/Provincial/Territorial Common Drug Review (CDR) which makes recommendations for listing drugs that the federal, provincial and territorial drug plans then consider. The CDR is a program of the Canadian Agency for Drugs and Technology in Health (CADTH), an independent, not-for-profit agency, funded by participating governments (all, except Quebec, which has a similar process through INESSS).
CADTH has implemented a process by which patient groups can contribute input into drug review and decision-making around public drug plan formulary listings. The Arthritis Society and Canadian Arthritis Patient Alliance prepare patient input submissions whenever a drug of interest to people living with arthritis is under consideration. We would like to gather your views and share them with the CDR. Your views will be anonymous.
The survey should take approximately 15 minutes to complete. Please submit your responses by Friday August 7th, 2020.
If you have any questions or comments, please contact Helen Anderson at handerson@arthritis.ca or Linda Wilhelm at lindaa.wilhelm@gmail.com. Feel free to email us if you’d prefer to provide your input by telephone.
The Common Drug review, as part of the CADTH review process, seeks to hear from patients about their disease experiences to help the reviewers better understand any unmet needs a new medication could help to address.
Background
All new drugs are submitted for review by the joint Federal/Provincial/Territorial Common Drug Review (CDR) which makes recommendations for listing drugs that the federal, provincial and territorial drug plans then consider. The CDR is a program of the Canadian Agency for Drugs and Technology in Health (CADTH), an independent, not-for-profit agency, funded by participating governments (all, except Quebec, which has a similar process through INESSS).
CADTH has implemented a process by which patient groups can contribute input into drug review and decision-making around public drug plan formulary listings. The Arthritis Society and Canadian Arthritis Patient Alliance prepare patient input submissions whenever a drug of interest to people living with arthritis is under consideration. We would like to gather your views and share them with the CDR. Your views will be anonymous.
The survey should take approximately 15 minutes to complete. Please submit your responses by Friday August 7th, 2020.
If you have any questions or comments, please contact Helen Anderson at handerson@arthritis.ca or Linda Wilhelm at lindaa.wilhelm@gmail.com. Feel free to email us if you’d prefer to provide your input by telephone.